Literature DB >> 22102625

Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: a potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial.

Bertram Pitt, Mihai Gheorghiade.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22102625     DOI： 10.1093/eurjhf/hfr150

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


× No keyword cloud information.
  2 in total

1.  Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Authors:  David E Lanfear; Hani N Sabbah; Steven R Goldsmith; Stephen J Greene; Andrew P Ambrosy; Angela J Fought; Mary J Kwasny; Karl Swedberg; Clyde W Yancy; Marvin A Konstam; Aldo P Maggioni; Faiez Zannad; Mihai Gheorghiade
Journal:  Circ Heart Fail       Date:  2012-12-12       Impact factor: 8.790

2.  Tolvaptan treatment in an adult Fontan patient with protein-losing enteropathy: a serial 23Na-MRI investigation.

Authors:  Julia Moosmann; Okan Toka; Peter Linz; Anke Dahlmann; Armin M Nagel; Mario Schiffer; Michael Uder; Robert Cesnjevar; Sven Dittrich; Christoph Kopp
Journal:  Ther Adv Chronic Dis       Date:  2021-04-16       Impact factor: 5.091
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.